Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-05-17
2011-05-17
Bland, Layla (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S024000, C514S025000, C536S004100, C536S029100
Reexamination Certificate
active
07943586
ABSTRACT:
The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neo-plastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxyglucose, wherein a linker, which includes a covalent bond, is attached to 2-deoxyglucose at the 2 position, and the linker is attached to a therapeutic or diagnostic agent. The invention also relates to methods of treating tumor disease and methods of making the novel compounds of the present invention. The agents of the present invention are superior to previous agents as they are targeted via GLUT transporters.
REFERENCES:
patent: 5622936 (1997-04-01), Wiessler et al.
patent: 6489302 (2002-12-01), Wiessler et al.
patent: 6548484 (2003-04-01), Christian
patent: 6989140 (2006-01-01), Tidmarsh et al.
patent: 2002/0198157 (2002-12-01), Pandey et al.
patent: 2003/0181393 (2003-09-01), Lampidis et al.
patent: 2004/0029815 (2004-02-01), Tidmarsh et al.
patent: 2004/0152665 (2004-08-01), Anastassiades
patent: WO 92/11012 (1992-07-01), None
patent: WO 01/82926 (2001-11-01), None
patent: WO 03/099285 (2003-12-01), None
patent: WO 2004/062614 (2004-07-01), None
Kozyrev et al. Tetrahedron Letters 1996, vol. 37, No. 36, pp. 6431-6434.
Dufes et al. Pharmaceutical Research, vol. 17, No. 10, 2000.
Daishu et al. Journal of Chinese Pharmaceutical Sciences 2001, 10 (4).
Fukuzumi et al. J. Phys. chem. A 2002, 106, 5105-5113.
Patani et al. Chem Rev. 1996, 96, 3147-3176.
Abraha, A., et al., “Inhibition of Tumor Cell Proliferation by Dexamethasone:31P NMR Studies of RIF-1 Fibrosarcoma cells Perfused in vitro,”NMR in Biomedicine 9:173-178, Wiley-Liss, Inc. (1996).
Achilefu, S., et al., “Novel Receptor-Targeted Fluorescent Contrast Agents for in Vivo Tumor Imaging,”Invest. Radiol. 35:479-485, Lippincott Williams & Wilkins, Inc. (2000).
Achilefu, S., et al., “Synthesis, In Vitro Receptor Binding, and In Vivo Evaluation of Fluorescein and Carbocyanine Peptide-Based Optical Contrast Agents,”J. Med. Chem. 45:2003-2015, American Chemical Society (May 2002).
Aiken, N.R., et al., “31P NMR Spectroscopic Studies of the Effects of Cyclophosphamide on Perfused RIF-1 Tumor Cells,”Magn. Reson. Med. 31:241-247, Williams & Wilkins (1994).
Alavi, A., and Reivich, M., “Guest Editorial: The Conception of FDG-PET Imaging,”Semin. Nucl. Med. 32:2-5, W.B. Saunders Company (Jan. 2002).
Baidoo, K. E., Mathews, W., and Wagner, H. N., Fluorescent imaging of deoxyglucose. 8th Intl. Conf: Peace through Mind/Brain Science Hamamatsu, Japan, Feb. 2-4, 2000.
Becker, A., et al., “Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands,”Nature Biotechnol. 19:327-331, Nature America, Inc. (2001).
Benaron, D.A., et al., “Enabling Molecular Imaging in the Operating Room: the Palomar™ Real-Time Room-Light Molecular Imaging System,” Molecular Imaging 2:S194, MIT Press (Jul. 2003).
Berkowitz, B.A. and Ackerman, J.J.H., “Proton Decoupled Fluorine Nuclear Magnetic Resonance Spectroscopy In Situ,”Biophys. J. 51:681-685, Biophysical Society (1987).
Bhujwalla, Z.M., et al., “Energy Metabolism, pH Changes, and Lactate Production in RIF-1 Tumors Following Intratumoral Injection of Glucose,”Int. J. Radiat. Oncol. Biol. Phys. 22:95-101, Pergamon Press (1991).
Bhujwalla, Z.M., et al., “Glucose Metabolism in RIF-1 Tumors after Reduction in Blood Flow: An In Vivo13C and31P NMR Study,”Magn. Reson. Med. 32:303-309, Williams & Wilkins (1994).
Binder C. et al., “Deregulated Simultaneous Expression of Multiple Glucose Transporter Isoforms in Malignant Cells and Tissues,”Anticancer Res. 17:4299-4304, J.G. Delinassios (1997).
Blokland, J.A., et al., “Positron emission tomography: a technical introduction for clinicians,”Eur. J. Radiol. 44:70-75, Elsevier Science Ireland Ltd. (Oct. 2002).
Braunschweiger, P.G., et al., “Potentiation of Interleukin 1 α Mediated Antitumor Effects by Ketoconazole,”Cancer Res. 50:4709-4717, American Association for Cancer Research (1990).
Briasoulis, E., et al., “Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group,”J. Clin. Oncol. 18:3535-3544, American Society of Clinical Oncology (2000).
Bugaj, J.E., et al., “Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform,”J. Biomed. Opt. 6:122-133, SPIE (2001).
Chance, B., et al., “Oxidation-Reduction Ratio Studies of Mitochondria in Freeze-trapped Samples,”J. Biol. Chem. 254:4764-4771, American Society for Biochemistry and Molecular Biology (1979).
Chance, B., et al., “Highly sensitive object location in tissue models with linear in-phase and anti-phase multi-element optical arrays in one and two dimensions,”Proc. Natl. Acad. Sci. USA 90:3423-3427, National Academy of Sciences (1993).
Chance, B., et al., “Precision localization of hidden absorbers in body tissues with phased-array optical systems,”Rev. Sci. Instrum. 67:4324-4332, American Institute of Physics (1996).
Chang, C.H.F., et al., “The Interactions of Gallium with Various Buffers and Chelating Agents in Aqueous Solution: Gallium-71 and Hydrogen-1 NMR Sstudies,”Bioinorg. Chem. 8:11-19, Elsevier North-Holland, Inc. (1978).
Chen, Y., et al., “Bacteriopurpurinimides: Highly Stable and Potent Photosensitizers for Photodynamic Therapy,”J. Med. Chem. 45:255-258, American Chemical Society (Jan. 2002).
Chen, Y., et al., “Near-infrared phase cancellation instrument for fast and accurate localization of fluorescent heterogeneity,”Rev. Sci. Instrum. 74:3466-3473, American Institute of Physics (Jul. 2003).
Chen, Y., et al., “Metabolism-enhanced tumor localization by fluorescence imaging: in vivo animal studies,”Optics Lett. 28:2070-2072, Optical Society of America (Nov. 2003).
Cohade, C., and Wahl, R.L., “PET Scanning and Measuring the Impact of Treatment,”Cancer J. 8:119-134, Jones and Bartlett Publishers, Inc. (Mar./Apr. 2002).
Colvin, M. and Hilton, J., “Pharmacology of Cyclophosphamid and Metabolites,”Cancer Treat. Rep. 65:89-95, U.S. National Cancer Institute (1981).
Colvin, M., “The Comparative Pharmacology of Cyclophosphamide and Ifosphamide,”Semin. Oncol. 9:2-7, Grune & Stratton, Inc. (1981).
Colvin, O.M., “An Overview of Cyclophosphamide Development and Clinical Applications,”Curr. Pharm. Design 5:555-560, Bentham Science Publishers B.V. (1999).
Colvin, O.M., et al.,“Role of Glutathione in Cellular Resistance to Alkylating Agents,”Adv. Enzyme Regul. 33:19-26, Pergamon Press Ltd. (1993).
Czernin, J., “Clinical Applications of FDG-PET in Oncology,”Acta Medica Austriaca 29:162-170, Blackwell Publishing Ltd. (Nov. 2002).
Czemin, J. and Phelps, M.E., “Positron Emission Tomography Scanning: Current and Future Applications,”Ann. Rev. Med. 53:89-112, Annual Reviews (Feb. 2002).
Deuel, R.K., et al., “Monitoring the Time Course of Cerebral Deoxyglucose Metabolism by31P Nuclear Magnetic Resonance Spectroscopy,”Science 228:1329-1331, American Association for the Advancement of Science (1985).
Dougherty, T.J., et al., “Photodynamic Therapy,”J. Natl. Cancer Inst. 90:889-905, Oxford University Press (1998).
Duvvuri, U., et al., “Quantitative T1pmagnetic Resonance Imaging of RIF-1 Tumors in Vivo: Detection of Early Response to Cyclophosphamide Therapy,”Cancer Res. 61:7747-7753, American Association for Cancer Research (2001).
Fiedor, J., et al., “Photodynamics of the Bacteriochlorophyll-Carotenoid System. 2. Infl
Chance Britton
Glickson Jerry D.
Zheng Gang
Bland Layla
Sterne Kessler Goldstein & Fox P.L.L.C.
The Trustees of the University of Pennsylvania
LandOfFree
Antineoplastic agents targeted via glut transporters does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antineoplastic agents targeted via glut transporters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antineoplastic agents targeted via glut transporters will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691396